Orchard Therapeutics (Europe) Limited

5 trials Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

0 Recruiting

5 Completed trials

2 Countries active

9 Unique IMPs

100% Results reported

Phase III

Phase I/II

Phase I (FiH)

Phase III: 3 Phase I/II: 1 Phase I (FiH): 1

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Metachromatic leukodystrophy 3

Top IMPs

ATIDARSAGENE AUTOTEMCEL 3 AUTOLOGOUS CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS GENETICALLY MODIFIED WITH THE LENTIVIRAL VECTOR IDUA LV, ENCODING FOR THE ALPHA-L-IDURONIDASE CDNA 2

All trials

5 total

A study to investigate the efficacy and safety of OTL-203 in subjects with mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) compared w… Ended

2022-500306-17-00 Phase III 2 countries AUTOLOGOUS CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS GENETICALLY MODIFIED W…
A clinical trial to evaluate the effect of OTL-200, a gene therapy treatment in patients with Late Juvenile (LJ) Metachromatic Leukodystroph… Ended

2024-511971-13-00 Phase III 1 country ATIDARSAGENE AUTOTEMCEL
Gene therapy study with autologous hematopoietic stem cells for patients affected by MPS-IH Ended

2024-514870-29-00 Phase I (FiH) 1 country AUTOLOGOUS CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS GENETICALLY MODIFIED W…
Gene therapy study using a frozen formulation of OTL-200 in patients with Metachromatic Leukodystrophy (MLD) Ended

2024-511970-66-00 Phase III 1 country ATIDARSAGENE AUTOTEMCEL
Hematopoietic stem cell gene therapy study Ended

2024-515253-25-00 Phase I/II 1 country ATIDARSAGENE AUTOTEMCEL

Showing 1–5 of 5 trials

← All sponsors A–Z